This is the authors' abstract. We don't add key points for this paper.
Summary. The capacity of peripheral blood leucocytes from 11 patients with acute myeloid leukaemia (AML) and 10 patients with chronic granulocytic leukaemia (CGL) to ingest and kill Candida albicans was tested in vitro. The patients with CGL were, for the most part, receiving chemotherapy and had peripheral leucocyte counts in the normal range, whereas none of the patients with AML had received therapy within the preceding 7 days and none had entered complete remission. Ingestion of Candida organisms was found to be normal in both groups of patients, but the killing activity (candidacidal index) of leucocytes from patients with AML was significantly impaired. Leucocytes from CGL patients killed engulfed Candida normally. It is postulated that the candidacidal defect in leucocytes from patients with AML has two components, one intrinsic to the leucocyte and the other due to a deficient (or inhibitory) factor in the patient's plasma.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Goldman et al. (1973) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: